Patients receiving palliative care often possess multiple risk factors and predisposing conditions for delirium. The impact of delirium on patient care in this population may also be far-reaching: affecting not only quality of remaining life but the dying process experienced by patients, caregivers, and the medical team as well. As palliative care focuses on comfort and symptom management, the approach to assessment and subsequent treatment of delirium in palliative care patients may prove difficult for providers to navigate. This article summarizes the multifactorial nature, numerous predisposing medical risk factors, neuropsychiatric adverse effects of palliative medications, pharmacokinetic changes, and challenges complicating delirium assessment and provides a systematic framework for assessment. The benefits, risks, and patient-specific considerations for treatment selection are also discussed.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision (DSM-IV-TR)Washington, DC: Author; 2000
2.
LiptzinB. An empirical study of delirium subtypes. Br J Psych. 1992;161:843–845.
3.
BrueraEBushSHWileyJParaskevopoulosTLiZPalmerJL. Impact of delirium and recall on the level of distress in patients with advanced cancer and their family caregivers. Cancer. 2009;115(4):2004–2012.
4.
BreitbartWGibsonCTremblayA. The delirium experience: delirium recall and delirium-related distress in hospitalizedpatients with cancer, their spouse/caregivers, and their nurses. Psychosomatics. 2002;43(3):183–194.
5.
BussMKVanderwerkerLCInouyeSKZhangBBlockSPrigersonHG. Associations between caregiver-perceived delirium in patients with cancer and generalized anxiety in their caregivers. J Pall Med. 2007;10(5):1083–1092.
6.
PierceSF. Improving end-of-life care: gathering suggestions from family members. Nursing Forum. 1999;34(2):5–14.
7.
SingerPAMartinDKKeltnerM. Quality end-of-life care: patients' perspectives. J Am Med Assoc. 1999;281(2):163–168.
8.
SteinhausserKEChristakisNAClippECMcNeillyMMcIntyreLTulksyJA. Factors considered important at the end of life for patients, family, physicians and other care providers. JAMA. 2000;284(19):2476–2482.
9.
InouyeSKCartpenterPA. Precipitating factors for delirium in hospitalized elderly persons: predictive model and interrelationship with baseline vulnerability. JAMA. 1996;275(11):852–857.
10.
MarcantonioERGoldmanLMangioneCMLudwigLEMuracaBHaslauerCM. A clinical prediction rule for delirium after elective noncardiac surgery. JAMA. 1994;271(2):134–139.
11.
RudolphJLJonesRNLevkoffSERockettCInouyeSKSellkeFW. Derivation and validation of a preoperative prediction rule for delirium after cardiac surgery. Circulation. 2009;119(2):229–236.
12.
MoritaTTeiYTsunodaJInoueSChiaraS. Underlying pathologies and their associations with clinical features of terminal delirium of cancer patients. J Pain Symptom Management. 2001;22(6):997–1006.
13.
LawlorPGGagnonBManciniIL. Occurrence, causes, and outcome of delirium in patients with advanced cancer. Arch Int Med. 2000;160(6):786–794.
14.
GraySLLaiKVLarsonEB. Drug-induced cognition disorders in the elderly: incidence, prevention and management. Drug Safety. 1999;21(2):101–122.
15.
AdunskyALevyRHeimMMizrahiEAradM. Meperidine analgesia and delirium in aged hip fracture patients. Arch Gerontol Geri. 2002;35(3):253–259.
16.
LawlorPG. The panorama of opioid-related cognitive dysfunction in patients with cancer: a critical literature appraisal. Cancer. 2002;94(6):1836–1853.
17.
BrueraEMacMillanKHansonJMacDonaldRN. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain. 1989;39(1):13–16.
18.
WalkerDJZacnyJP. Subjective, psychomotor, and physiological effects of cumulative doses of opioid mu agonists in healthy volunteers. J Pharm Exp Ther. 1999;289(3):1454–1464.
19.
EisendrathSJGoldmanBDouglasJDimatteoLVanDykeC. Meperidine-induced delirium. Am J Psychiatry. 1987;144(8):1062–1064.
20.
HallRPopkinMHenryL. Angel’s trumpet psychosis: a central nervous system anticholinergic syndrome. Am J Psych. 1997;134(3):312–314.
21.
HanLMcCuskerJColeMDe BellisMTheodoreWHPostRM. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Int Med. 2001;161(8):1099–1105.
22.
FlackerJMCummingsVMachJRBettinKKielyDKWeiJ. The association of serum anticholinergic activity with delirium in elderly medical patients. Am J Geri Psych. 1998;6(1):31–41.
23.
CaeiroLFerroJMClaroMICoehloJAlbeguerwueRFigueiraML. Delirium in acute stroke: a preliminary study of the role of anticholinergic medications. Euro J Neuro. 2004;11(10):699–704.
24.
TuneLEBylsmaFW. Benzodiazepine-induced and anticholinergic-induced delirium in the elderly. Int Psychogeri. 1991;3(2):397–408.
25.
MachJRDyskenMWKuskowskiMRichelsonEHoldenLJilkKM. Serum anticholinergic activity in hospitalized older persons with delirium: a preliminary study. J Am Geri Soc. 1995;43(5):491–95.
26.
AgarMCurrowDPlummerJSeidelRCarnahanRAbernathyAP. Changes in anticholinergic load from regular prescribed medications in palliative care as death approaches. Palliative Med. 2009;23(3):257–265.
27.
AgostiniJVLeo-SummersLSInouyeSK. Cognitive and other adverse effects of diphenhydramine use in hospitalized older patients. Arch Intern Med. 2001;161(17):2091–2097.
28.
PetersonLPopkinM. Neuropsychiatric effects of chemotherapeutic agents for cancer. Psychosomatics. 1980;21(2):141–153.
29.
VerstappenCCPHeimansJJHoekmanKPostmaTJ. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs. 2003;63(15):1549–1563.
30.
DenicoffKDRubinowDRPapaMZ. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med. 1987;107(3):293–300.
31.
Keime-GuibertFNapolitanoMDelattreJY. Neurological complications of radiotherapy and chemotherapy. J Neurol. 1998;245(11):695–708.
32.
StiefelFCBriebartWSHollandJC. Corticosteroids in cancer: neuropsychiatric complications. Cancer Investigat. 1989;7(5):479–491.
VincentFM. The neuropsychiatric complications of corticosteroid therapy. Compr Ther. 1995;21(9):524–528.
35.
HideakiK. Antiepileptic drugs and psychiatric disorders: mechanism involved in manifestation of psychic symptoms of high blood level of antiepileptics. Psychiatry Clin Neurosci. 2008;37(3):283–289.
36.
EttingerAB. Psychotropic effects of antiepileptic drugs. Neurology. 2006;67(11):1916–1925.
37.
JeshiAA. Paranoia and agitation associated with olanzapine treatment (letter). Can J Psychiatry. 1998;43(2):195–196.
38.
JohnVRappMPiesR. Aggression, agitation, and mania with olanzapine (letter). Can J Psychiatry. 1998;43(10):1054.
39.
Eli Lilly and Company Product Information: ZYPREXA RELPREVV Extended Release IM injectable Suspension, Olanzapine Extended Release IM Injectable Suspension. Indianapolis, IN: Eli Lilly and Company, 2009
40.
Ravona-SpringerRDolbergOTHirschmannSGrunhausL. Delirium in elderly patients treated with risperidone: a report of three cases (letter). J Clin Psychopharmacol. 1998;18(2):171–172.
41.
TavcarMZDernovsekR. Risperidone-induced delirium (letter). Can J Psychiatry. 1998;43(2):194.
42.
NozakiO. Psychiatric manifestations accompanying interferon therapy for patients with chronic hepatitis C: an overview of cases in Japan. Psychiatry Clin Neurosci. 1997;51(4):175–180.
SuterCCWestmorelandBFSharbroughFW. Electroencephalographicabnormalities in interferon encephalopathy: a preliminary report. Mayo Clin Proc. 1984;59(12):847–850.
45.
BuxtonIPharmacokinetics and pharmacodynamics: the dynamics of drug absorption, distribution, action, and elimination. In: Brunton LL, ed. In: Goodman & Gillman’s The Pharmacological Basis of Therapeutics. 11e2006; USA: The McGraw-Hill Companies, Inc
46.
GutsteinHBAkilHOpioid analgesics. In: Brunton LL, ed. In: Goodman & Gillman’s The Pharmacological Basis of Therapeutics. 11e2006; USA: The McGraw-Hill Companies, Inc
47.
CharneyDSMihicSJHarrisRAHypnotics and Sedatives. In: BruntonLL, ed. In: Goodman & Gillman’s The Pharmacological Basis of Therapeutics. 11e2006; USA: The McGraw-Hill Companies, Inc
48.
HauserPDevinskyODeBellisMTheodoreWHPostRM. Benzodiazepine withdrawal delirium with catatonic features. Arch Neurol. 1989;46(6):696–699.
49.
FangCKChenHWLiuSILinCJTsaiLYLaiYL. Prevalence, detection and treatment of delirium in terminal cancer inpatients: a prospective survey. J Clin Oncol. 2008;38(1):56–63.
50.
LawlorPGBrueraE. Delirium in patients with advanced cancer. Hematol Oncol Clin North Am. 2002;16(5):701–714.
51.
BrueraEMillerLMcCallionJMacmillanKKreftingLHansonJ. Cognitive failure in patients with terminal cancer: a prospective study. J Pain Symptom Manag. 1992;7(4):192–195.
52.
BreitbartWRosenfeldBRothASmithMJCohenKPassikS. The memorial delirium assessment scale. J Pain Symptom Manag. 1997;13(3):128–137.
53.
LawlorPGNekolaichukCGagnonBManciniILPereira BrueraED. Clinical utility, factor analysis, and further validation of the Memorial Delirium Assessment Scale in patients with advanced cancer: assessing delirium in advanced cancer. Cancer. 2007;88(12):2859–2867.
54.
SarhillNWalshDNelsonKALeGrandSDavisMP. Assessment of delirium in advanced cancer: the use of the bedside confusion scale. Am J Hospice Pall Med. 2001;18(5):335–341.
55.
BreitbartWDiagnosis and management of delirium in the terminally il. In: PortenoyR (Ed.), Topics in Palliative Care. 1998;Vol 5:New York: Oxford University Press, 303.
56.
LonerganEBrittonAMLuxenbergJ. Antipsychotics for delirium. Cochrane Database System Rev. 2007. ;((Issue 2):Art. No.: CD005594
57.
MarkowitzJD. Narasimhan M. Delirium and antipsychotics: a systematic review of epidemiology and somatic treatment options. Psychiatry (Edgemont). 2008;5(10):29–36.
58.
SchneiderLSDagermanKSInselP. Risk of death with atypical antipsychotic drug treatment for dementia: metaanalysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934–1943.
59.
SchneeweissS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Can Med Assoc J. 2007;176(5):627–632.
60.
GillS. Antipsychotic drug use and mortality in older adults with dementia. Ann Int Med. 2007;146(11):775–786.
61.
BreitbartWRoccoMPlattMM. A double blinded trial of haloperidol, chlorazepam, and lorazepam in the treatment of delirium in hospitalized AIDs patients. Am J Psych. 1996;153(5):231–237.
62.
KhanLCLustikSJ. Treatment of a paradoxical reaction to midazolam with haloperidol. Anesth Analg. 1997;85(1):213–215.
63.
MarcantonioERJuarezGGoldmanLMangioneCMLudwigLELindE. The relationship of postoperative delirium with psychoactive medications. JAMA. 1994;272(19):1518–1522.
64.
CrimminsEMSaitoYIngegneriD. Trends in disability-free life expectancy in the United States, 1970-1990. Popul Develop Rev. 1997;23(5):555–572.
65.
BrueraERancoJJMaltoniMWantabeSSuarez-AlmazorM. Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration and opioid titration. J Pain Symptom Manag. 1995;10(4):287–291.
66.
JacksonKCLipmanAG. Drug therapy for delirium in terminally ill adult patients. Cochrane Database System Rev. 2004;Issue 2. Art. No:CD004770.
67.
BrueraESalaRRicoMAMoyanoJCentenoCWilleyJPalmerJL. Effects of parenteral hydration in terminally ill cancer patients: a preliminary study. J Clin Onco. 2005;23(10):2366–2371.
68.
CerchiettiLNaviganteASauriAPalazzoF. Hypodermoclysis for control of dehydration in terminal-stage cancer. Int J Palliat Nurs. 2000;6(8):370–374.
69.
MoritaTHyodoIYoshimiTIkenagaMTamuraYYoshizawaA. Association between hydration volume and symptoms in terminally ill cancer patients with abdominal malignancies. Ann Oncol. 2005;16(4):640–647.
70.
ViolaRA. In: Studying Fluid Status and the Dying: The Challenge of Clinical Research in Palliative Care. 1997; Canada: University of Ottawa
71.
WallerAHershkowitzMAdunskyA. The effect of intravenous fluid infusion on blood and urine parameters of hydration and on state of consciousness in terminal cancer patients. Am J Hosp Palliat Care. 1994;11(4):22–27.
72.
MoritaTBitoSKoyamaHUchitomiYAdachiI. Development of a national clinical guideline for artificial hydration therapy for terminally ill patients with cancer. J Palliat Med. 2007;10(3):770–780.
73.
SlatkinNERhinerMBoltonTM. Donepezil in the treatment of opioidinduced sedation: report of six cases. J Pain Symptom Manag. 2001;21(5):425–438.
74.
BrueraEStrasserFShenLPalmerJLWilleyJDirverLC. The effects of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain: a pilot study. J Pain Symptom Manag. 2003;26(5):1049–1054.
